Expression element combination, expression vector, host, application and assembly method
Patent Information
- Application Number
- CN202280094043.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-23
- Publication Date
- 2024-12-03
AI Technical Summary
Existing phage genome large fragment assembly technology has problems such as low success rate, long experimental cycle and high technical threshold. In particular, there is a lack of effective methods for direct assembly and activation in E. coli.
Using the method of combining the lambda Red homologous recombination system and pRARE plasmid, through the technology of combining in vitro Gibson Assembly assembly and Escherichia coli in vivo assembly, the direct assembly and activation of the phage genome is achieved, avoiding cumbersome screening steps, improving assembly efficiency and success rate.
It has achieved the successful assembly and activation of multiple large phage genome fragments, shortened the experimental cycle, improved the assembly success rate, simplified the process, and is suitable for the improvement of phage therapy and the synthesis of artificial phages.
Smart Images

Figure 00000046_0000 
Figure 00000046_0001 
Figure 00000046_0002
Abstract
Description
Expression element combination, expression vector, host, application and assembly method Technical Field
[0001] The present invention relates to the field of genome fragment assembly, and in particular to an expression element combination, an expression vector, a host, an application and an assembly method of a phage genome fragment. Background Art
[0002] With the increasing application of phage therapy, in vitro experiments and clinical data have shown that the effectiveness of phage therapy using natural phages has certain limitations, and even natural phage tolerance has emerged. This limitation is due to the strict host specificity of phages and a very narrow bactericidal spectrum. Generally, a phage can only target and kill one type of bacteria, or one strain of a bacteria. This is mainly determined by the molecular structure and complementarity between the phage adsorption protein and the host cell membrane receptor. One reason for tolerance may be the natural genetic immune system of some bacteria (CRISPR-Cas system).
[0003] To address the above issues, natural phage cocktail therapy and natural phage cocktail therapy combined with antibiotics are currently the most common approaches. However, these two approaches do not fundamentally address the narrow host range of phages. In recent years, scientists have been experimenting with genetic engineering methods to modify phages and synthesize new artificial phages to broaden their host range. Currently, the main technologies for assembling large (≥10kb) and multiple (≥4) artificial phage fragments include direct in vivo (yeast) assembly and in vitro assembly (Gibson Assembly and Golden Gate Assembly).
[0004] In 2012, Jaschke et al. used PCR products and synthetic fragments to directly assemble a 5.4kb phage X174 genome in yeast for the first time, and successfully activated it in Escherichia coli to obtain plaques. In September 2015, the journal Cell Systems reported the successful assembly of 5-10 fragments ranging in size from 1.3 to 10.1kb (including the plasmid vector YAC 3.0kb) using the natural homologous recombination system in Saccharomyces cerevisiae. The assembled phage genomes ranged in length from 37 to 45kb. In August 2020, the journal American Society for Microbiology reported the successful in vitro assembly of 3-4 phage genome fragments of 8-15kb using long-fragment PCR and Gibson Assembly, with an overall length of 39-62kb. In December 2020, the research and development team of New England Biolabs (NEB) in the United States successfully assembled a T7 phage genome (40kb) consisting of 52 fragments ranging in length from 148 to 1735bp using the in vitro Golden Gate Assembly method. The above two types of experimental techniques either assemble the phage genome in vitro and activate it in E. coli, or assemble it directly in yeast, release it after obtaining the phage genome, and then activate it in E. coli. To date, there have been no reports of direct assembly and activation of large phage genome fragments in E. coli.
[0005] In addition, Professor Zhang Youming's team at Shandong University independently developed the ExoCET large fragment plasmid direct cloning method in 2017. This method clones single-fragment bacterial or mammalian genomes with a minimum of 8kb and a maximum of 106kb into a 2.2kb linear plasmid vector. In 2019, the team used the ExoCET experimental technology to directly clone 12 PCR products with a length of 1.5-2.5kb into a 2.1kb linear vector, with a total length of 25.4kb. New England Biolabs (NEB) in the United States has developed a kit HiFi DNA Assembly, this kit is more efficient and accurate than the current conventional Gibson Assembly Master Mix / Cloning kit, and is suitable for molecular cloning of single large fragments (≥10kb) or multiple fragments (≥4). Currently, a 12kb DNA fragment has been successfully cloned into a 7.4kb plasmid. TM TOPO TM XL-2 Complete PCR Cloning Kit, which can clone 13kb long PCR products simply, efficiently and accurately.
[0006] Currently, the synthesis of artificial phages faces a technical bottleneck in genome assembly. At this stage, in vitro assembly or in vivo assembly in yeast are mostly used. The success rate of in vitro assembly of large genome fragments is extremely low; the experimental cycle of in yeast assembly technology is long and the technical threshold is high.
[0007] 1. In vitro Gibson Assembly:
[0008] Gibson Assembly mainly relies on homologous recombination of homologous sequences at the ends of DNA. The assembly efficiency decreases with the size and number of DNA fragments. The success rate of assembling phage genomes by this method is low.
[0009] 2. In vitro Golden Gate Assembly:
[0010] Golden Gate Assembly utilizes type IIS restriction endonucleases to generate DNA fragments with short single-stranded overhangs and DNA ligase to join the fragments. Assembly relies on a target vector containing a resistance selection marker for screening positive clones, but this can be prone to false positives. Subsequent PCR and sequencing verification is still required, increasing experimental time and costs.
[0011] 3. Direct assembly in yeast:
[0012] 1) This method has a high technical threshold and low universality;
[0013] 2) This method has a long experimental cycle (yeast needs to grow at 30°C for 2-3 days; the experiment requires two steps: assembly of the phage genome in yeast and verification of phage activation in E. coli).
[0014] In summary, providing a method for assembling genome fragments, especially phage genome fragments, has important practical significance.
[0015] Summary of the Invention
[0016] In view of this, the present invention provides expression element combinations, expression vectors, hosts, applications and assembly methods of genomic fragments.
[0017] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0018] In a first aspect, the present invention provides an expression element combination, including but not limited to:
[0019] (I), expression elements in the pRARE plasmid; and
[0020] (II) Expression elements of the lambda Red homologous recombination system.
[0021] In some specific embodiments of the present invention, the expression elements of the lambda Red homologous recombination system in the expression element combination include but are not limited to exo, bet and gam.
[0022] In a second aspect, the present invention further provides an expression vector comprising the expression element combination according to claim 1 or 2.
[0023] In some specific embodiments of the present invention, the expression vector includes but is not limited to pRARE plasmid and pKD46 plasmid.
[0024] In a third aspect, the present invention also provides a host transformed or transfected with the expression vector.
[0025] In some specific embodiments of the present invention, the host is a prokaryotic organism or a eukaryotic organism, including but not limited to one or more of bacteria, actinomycetes, rickettsia, chlamydia, mycoplasma, cyanobacteria, archaea, yeast and mold.
[0026] In some embodiments of the present invention, the bacteria include but are not limited to Gram-negative bacteria or Gram-positive bacteria;
[0027] Preferably, the Gram-negative bacteria include but are not limited to Escherichia coli; more preferably, the Escherichia coli include but are not limited to Escherichia coli DH10B and Stellar;
[0028] Preferably, the Gram-positive bacteria include but are not limited to cell wall-deficient L-form bacteria; more preferably, the cell wall-deficient L-form bacteria include but are not limited to L-form Listeria.
[0029] Based on the above research, the fourth aspect of the present invention further provides the use of the expression element combination, the expression vector, or the host in genome fragment assembly.
[0030] In a fifth aspect, the present invention also provides one or more uses of the expression element combination, the expression vector, or the host in molecular cloning, synthesis of artificial phages, phage therapy, preparation of phage therapy products, detection of microorganisms, preparation of products for detecting microorganisms, prevention and / or treatment of infections or diseases caused by microorganisms, or preparation of drugs for prevention and / or treatment of infections or diseases caused by microorganisms.
[0031] In some specific embodiments of the present invention, the fragments include but are not limited to:
[0032] (I), fragments <2 kb; and / or
[0033] (II), fragments ≥2 kb and <7 kb; and / or
[0034] (III), fragments ≥7 kb and <10 kb; and / or
[0035] (IV), fragments ≥7 kb and <10 kb; and / or
[0036] (V), fragments ≥10 kb.
[0037] In some specific embodiments of the present invention, the number of the fragments includes but is not limited to:
[0038] (I), <5; and / or
[0039] (II), ≥5 and <10; and / or
[0040] (III), ≥10 and <15; and / or
[0041] (IV), ≥15.
[0042] In a sixth aspect, the present invention also provides a method for assembling genomic fragments, which assembles genomic fragments based on the expression element combination, the expression vector, or the host.
[0043] In some specific embodiments of the present invention, the assembly includes but is not limited to:
[0044] (I), direct assembly in the host; and / or
[0045] (II), in vitro Gibson Assembly and in vivo assembly in the host.
[0046] In some specific embodiments of the present invention, the assembly method includes but is not limited to the following steps:
[0047] Step A: Obtain the genome fragments to be assembled;
[0048] Step B: perform in vitro Gibson Assembly;
[0049] Step C: assembly in the host body;
[0050] The assembly method may include step B or may not include step B.
[0051] In some specific embodiments of the present invention, the fragments involved in the assembly method include but are not limited to:
[0052] (I) There is a homologous region of at least 40 to 100 bp at the end; and / or
[0053] (II) When the number of the fragments is large (>6) or large (>2kb), the length of the homology arms is increased, while ensuring that the absolute value of the secondary structure free energy of the homology region at 50°C is small (as small as possible to avoid the secondary structure formed at the end affecting the terminal homologous recombination. The maximum absolute value of the homology arm free energy of the successfully assembled fragments is currently 15.74kcal / mol).
[0054] In some specific embodiments of the present invention, the reaction temperature of the in vitro Gibson Assembly includes but is not limited to 37°C to 50°C;
[0055] Preferably, the reaction temperature of the in vitro Gibson Assembly includes but is not limited to:
[0056] (I), 42°C or 50°C; and / or
[0057] (II), 37°C to 42°C; and / or
[0058] (III), 42℃~50℃.
[0059] In some specific embodiments of the present invention, the reaction time of the in vitro Gibson Assembly in step B of the assembly method includes but is not limited to 15 min to 105 min;
[0060] Preferably, the reaction time of the in vitro Gibson Assembly includes but is not limited to:
[0061] (I), 15 min, 75 min or 105 min; and / or
[0062] (II), 15 minutes to 75 minutes; and / or
[0063] (III), 75min~105min.
[0064] In some specific embodiments of the present invention, in the in vitro Gibson Assembly system, the amount of the fragment is no less than 30 fmol;
[0065] Preferably, the amount of the fragment includes but is not limited to:
[0066] (I), 30 fmol to 60 fmol; and / or
[0067] (II), >60fmol.
[0068] The genome, as used in this invention, refers to the complete set of genetic material, or all nucleic acids carrying genetic information, in a cell or organism. This includes nucleic acids on all chromosomes and, for eukaryotes, also includes nucleic acids on mitochondria. Differences exist between organisms, and these differences are determined by their genomes. Genome sizes vary greatly, ranging from as little as 5,000 base pairs (bp), such as in simple viruses, to as large as 1011 bp, as in some higher plants. Genome size is not directly related to an organism's complexity. The position of certain components within the genome is not fixed, and genome size or gene number is not absolutely fixed between individuals of the same species. Variations in genome structure can even lead to functional variations. Despite this, genomes in various organisms share basic structural characteristics. The human genome consists of 3.2109 bp of DNA, comprising the nuclear chromosomal genome and the mitochondrial genome within the cytoplasm. Approximately half of the nuclear chromosomal genome consists of different repetitive sequences, containing 25,000 to 35,000 genes. The genome controls the growth and development of an organism and governs its vital activities. To understand the essence of life, we must first understand the genome, master all the nucleic acid sequences of the genome, analyze all the genetic information of the genome, and understand the organizational structure of genetic information and its expression in organisms.
[0069] Prokaryotic Genomes: Prokaryotic genomes are relatively small, containing a low amount of DNA. Much of the information in prokaryotic genomes is required for basic cellular functions, such as constructing and replicating DNA, producing new proteins, and obtaining and storing energy. Unlike eukaryotic DNA, prokaryotic genomes have a very high gene density. The vast majority of the DNA molecule encodes proteins, with only a very small portion not transcribed. Bacteria contain both chromosomes and extrachromosomal plasmid DNA. The genomic DNA of Escherichia coli is a single double-stranded circular DNA molecule, and some bacteria also contain small circular double-stranded DNA in the cytoplasm. Extrachromosomal DNA may also contain genetic information, enabling self-replication and transmission to daughter cells.
[0070] Eukaryotic Genomes: Eukaryotic organisms are far more complex than prokaryotes in various aspects, including a rich internal membrane system and an intricate genetic information expression system. Eukaryotic genomes are significantly larger than prokaryotic genomes, with complex organization and high information content. Protein-coding regions comprise only a small portion of the entire DNA sequence, while non-coding sequences make up a significant portion. Eukaryotic gene structure is also far more complex and varied than that of prokaryotes. Eukaryotic cells contain organelles, such as mitochondria and chloroplasts. These organelles also contain DNA, but unlike nuclear genomic DNA, they are typically small, circular, double-stranded DNA molecules.
[0071] Most eukaryotic genes are composed of protein-coding and non-protein-coding sequences. The coding sequences within a gene are called exons, while the non-coding sequences are called introns. Within a structural gene, the exons encoding different regions of a protein are not arranged contiguously. Instead, they are often separated by introns of varying lengths, forming a mosaic arrangement. Therefore, eukaryotic genes are sometimes referred to as split genes. The number and size of introns vary greatly between genes. For example, the collagen gene, which is approximately 40 kb long, has at least 40 introns, ranging from as short as 50 base pairs to as long as 2000 base pairs. Many eukaryotic genes have numerous, sometimes very large, introns. For example, the gene associated with human cystic fibrosis contains 24 introns, totaling over 1 Mb in length. A few genes, such as histones, have no introns at all. The physiological functions of introns are currently unknown.
[0072] Many exons encode discrete structural and functional units of proteins. For example, the central exon of the myoglobin and hemoglobin genes encodes a heme-binding region that reversibly binds to oxygen. Other exons exclusively encode α-helical segments that insert the protein into the cell membrane. A single domain of a protein may be encoded by a single exon. One hypothesis suggests that during evolution, new proteins arise through the rearrangement of exons encoding discrete structural units, structural components, and catalytic sites. This intermixing of exons is a rapid and efficient method for generating new genes. Splitting genes also offers the advantage that, through alternative splicing, the newly generated RNA can produce a family of related proteins, a group of proteins that evolves according to a developmental program, resulting in variations in a fundamental property.
[0073] A key feature of eukaryotic gene cleavage structure is the highly conserved and specific base sequence of the exon-intron junction. The exon-intron junction, also known as the boundary sequence, is the boundary between exons and introns. Although very short, the exon-intron junction is highly conserved. This conserved sequence is closely linked to the splicing mechanism and serves as the signal sequence for RNA splicing.
[0074] Conserved sequences at the exon-intron junctions are present in almost all genes of higher eukaryotes, suggesting that a common splicing mechanism may exist in these genes. However, such conserved sequences are absent in mitochondrial genes, suggesting that different types of processing may occur.
[0075] A complete gene includes not only the coding region but also specific sequences of varying lengths on either side of the 5' and 3' ends. Although these sequences do not encode amino acids, they nonetheless play an important role in gene expression. Therefore, the strict molecular biological definition of the term "gene" is the entire nucleotide sequence necessary to produce a polypeptide chain or functional RNA.
[0076] At the initiation of gene expression, RNA polymerase binds to a specific nucleic acid sequence in the 5'-upstream region of a gene and begins transcription, synthesizing an RNA copy of the gene. This nucleic acid sequence is called a promoter. The promoter determines the direction, speed, and accuracy of DNA transcription. RNA polymerase must accurately identify the starting point of gene transcription. When searching for the start point of a gene, RNA polymerase cannot look for any single nucleotide because the frequency of occurrence of a single nucleotide in a cell's DNA is very high. However, specific combinations of nucleotides are less likely to occur randomly, and the greater the number of nucleotides involved, the smaller the probability of such a combination. If all nucleotides occur with equal probability, the probability of a specific nucleotide sequence occurring alone is P = (1 / 4)n, where n is the number of nucleotides. Prokaryotic RNA polymerase scans the entire DNA strand, searching for a specific nucleotide sequence of approximately 13 nucleotides that marks the start of a gene (one nucleotide represents the transcription start site, six nucleotides are located 10 bases upstream of the start site, and another six nucleotides are located 35 bases upstream). These promoter sequences are fixed relative to each other. Because most prokaryotic genomes are only a few million nucleotides long, the probability of these promoter sequences merging is about one in 70 million, which is sufficient for RNA polymerase to reliably and uniquely identify the start of a gene. Eukaryotic genomes are several orders of magnitude larger than prokaryotic genomes, and accordingly, eukaryotic RNA polymerase must recognize more complex and longer promoter sequences to reliably identify the start of a gene.
[0077] By analyzing and comparing the promoters of many genes, we have discovered a highly conserved promoter sequence. As mentioned earlier, for prokaryotic genes, 10 bp upstream of the transcription start site, there is a purine box sequence: T80A90T45A60A50T96. The numbers in the lower right corner of the letters indicate the frequency of occurrence of the corresponding bases. Furthermore, 35 bp upstream of the transcription start site, there is a conserved sequence: T82T84G78A65C54A45. For eukaryotic genes, 30 bp upstream of the transcription start site, there is a TATA box, 80 bp upstream, and a CAAT box. Between 80 and 110 bp upstream, there is a GCCACACCC or GGGCCGGG sequence, known as a GC box.
[0078] A promoter is defined as a DNA sequence with a relatively fixed position upstream of the transcription start site, including the TATA box, CAAT box, and GC box, generally located 150 bp upstream from the transcription start site. These conserved upstream sequences are collectively referred to as upstream promoter elements (UPEs).
[0079] The TATA box functions differently from the other two UPEs. The former's primary function is to precisely initiate transcription. If the TATA box is removed or mutated, the relative decrease in transcriptional production is less pronounced than after mutations to the CAAT or GC boxes, but the resulting RNA product has been found to have an unstable initiation point. The CAAT and GC boxes primarily control the frequency of transcription initiation and play little role in determining the initiation site. The CAAT box has the greatest impact on the frequency of transcription initiation; any change in a single base in this region significantly affects the transcription intensity of the target gene, whereas substitutions of one or two bases elsewhere in the promoter region have little effect on transcription intensity. Furthermore, inserting nucleotides between the TATA box and the adjacent UPE can also weaken transcription. Although the three aforementioned UPE sequences all have important functions, not every gene's promoter region contains all three.
[0080] While promoters are crucial for transcription, are the sequences upstream of the promoter unrelated? Studies of the SV40 virus have shown that changes in certain sequences upstream of the promoter can significantly reduce transcriptional activity. These sequences, which normally enhance transcription, are called enhancers. Enhancers can typically increase transcriptional frequency by 10-200 times.
[0081] Enhancers have several notable characteristics: (1) The sequence of an enhancer is long, up to hundreds of base pairs. Sometimes it is a repetitive sequence, often containing a core sequence "(G)TGGA / TA / TA / T(G)". (2) The range of action is relatively long, and it can be thousands of bases away from the gene it acts on. (3) The action is not directional: the sequence is reversed and still has the same effect; (4) The position is not fixed: it can be upstream of the 5' end of a gene, downstream of the 3' end, or even within the intron of the gene. (5) Enhancers are generally tissue or cell specific. (6) The activity of an enhancer is related to its spatial directionality in the DNA double helix structure.
[0082] In addition to promoters and enhancers, there is also a negative regulatory element, the silencer, which can inhibit gene expression or selectively express genes.
[0083] Single-copy genes and gene families: Genes that occur only once in a genome are called single-copy genes. Single-copy genes are often protein-coding and are generally complex. These genes are often fragmented, meaning their coding regions are discontinuous. Eukaryotes also have transcription units similar to the operon structure in prokaryotes. These primary transcripts can produce more than one protein through different splicing patterns, meaning that a single DNA sequence can encode multiple proteins. 25% to 50% of protein-coding genes in eukaryotic cells exist as single genes in the genome, while the remaining protein-coding genes belong to gene families consisting of two or more similar genes. During evolution, multiple genes diverge from a single ancestral gene, forming a group of structurally and functionally related genes that may be clustered or dispersed throughout the genome. This group of genes, derived from a common ancestral gene and encoding similar but not identical proteins, is called a gene family. The proteins encoded by these genes are called protein families. Gene families vary in size, ranging from just a few genes to hundreds of genes. The gene families corresponding to α-globin and β-globin are the most studied gene families.
[0084] Repeat sequences: There are a large number of repeat sequences in the DNA of eukaryotic cells, especially in vertebrates. Repeat sequences can be roughly divided into three categories, namely low-repeat sequences, medium-repeat sequences and high-repeat sequences.
[0085] The number of repetitions of moderately repetitive sequences is between 10 and 105, accounting for 10% to 40% of the total DNA. For example, moderately repetitive sequences account for 20% of the mouse genome and 15% of that of fruit flies.
[0086] Highly repetitive sequences have a repetition frequency greater than 106, and the basic repetitive sequence length ranges from a few bases to several hundred bases or longer, accounting for 10% to 60% of the genome. Highly repetitive sequences can be divided into the following categories based on their length: (1) Satellite DNA: The repetitive sequence length ranges from 5 to 200 bp. These sequences are clustered together and arranged in tandem, with a total length of up to 100 mb (mega base). They are not highly polymorphic in the human population. (2) Minisatellite DNA: The repetitive sequence length ranges from 5 bp to several dozen bp, arranged in tandem, with a total length between 0.5 and 30 kb. This type of repetitive sequence is highly polymorphic in the human population. (3) Microsatellite DNA: The repetitive sequence length ranges from 2 to 6 bp, and is also highly polymorphic.
[0087] The genome is often viewed as static, with changes considered only on an evolutionary scale. However, the structure of the genome is not completely static; it is subject to change. Variation is ubiquitous in the biological world, occurring with each generation; no two individuals are exactly alike. Heritable variation includes gene mutation, gene recombination, and chromosomal aberration. A gene mutation refers to a change in the DNA sequence of a gene. Currently, the most well-understood form of molecular evolution is point mutation, or a single-base mutation within a nucleic acid sequence. A single-base mutation occurs when one base changes to another, either by inserting a new base into the sequence or deleting an existing base. Insertions or deletions within coding regions can cause a gene's reading frame to shift, disrupting the original codons and leading to abnormal gene transcription.
[0088] Many mutations have minimal impact on an organism. Mutations occurring within introns generally have no significant effect. However, mutations occurring at intron boundaries may affect transcriptional splicing. Mutations occurring at the third codon position, due to codon degeneracy, have little effect on the protein level. Even mutations that alter the protein sequence are often neutral. Of course, some point mutations are lethal, while others cause disease. Point mutations are rarely beneficial.
[0089] Genetic recombination and gene mobility are the driving forces of biological evolution and are of great biological significance. Genetic recombination occurs when DNA sequences from two or more different parents combine to form a new DNA sequence. Genetic recombination is a universal phenomenon in the biological world. Homologous recombination is the exchange of any two DNA sequences that share a homologous sequence. Homologous recombination requires the presence of homologous sequences between the two DNA molecules, regardless of the actual sequence order. As long as the two DNA molecules are similar, and the longer the segment of similarity, the higher the frequency of recombination. If the homologous sequence is too short, recombination is unlikely to occur. Homologous recombination is also a key mechanism for DNA damage repair. When a damaged strand needs to be repaired and the complementary strand cannot serve as a template, another homologous sequence is used to repair the damaged strand using the homologous recombination repair mechanism. Another type of recombination is site-specific recombination, which occurs within a specific short sequence region. During recombination, precise cleavage and ligation reactions occur without DNA loss or synthesis. There are also mobile gene sequences in the genome that can move from one part of a chromosome to a new location on the same chromosome or another chromosome. The movement of a gene from one location to another through various means is called gene movement. Genes that can move are called mobile genes. Mobile genes are typically moved via transposons. Recombination and movement can create new sequences and functions, or alter the functions of existing sequences.
[0090] Chromosomes may undergo aberrations, resulting in changes in genetic material. Chromosomal aberrations include chromosome loss, translocation, and displacement. These changes are actually changes in the DNA molecule. For example, the partial loss of a chromosome is actually the loss of a portion of the DNA molecule. Variation is a fundamental condition for evolution. The molecular mechanisms of evolution are gradually being understood. By comparing sequences of related molecules, we can understand the evolutionary relationships between species. Similarly, the similarities and differences between related molecules provide important information about their structure and function. Molecular evolution also involves selection and inheritance. Inheritance requires that genes from parents be passed on to offspring, while selection dictates that beneficial mutations be retained.
[0091] Human genome: The coding region of the human genome accounts for less than 3% of all DNA sequences, and the number of genes is between 25,000 and 35,000. Repetitive sequences account for a large portion of the human genome, approximately 50%, and these repetitive sequences may or may not have certain functions. The repetitive sequences in the human genome can be divided into four types: (1) short interspersed elements (SINEs); (2) long interspersed elements (LINEs); (3) long terminal repeat elements (LTRs); and (4) DNA transposons. The remaining DNA sequences in the genome include promoters, transcriptional regulatory sequences, and other sequences of unknown nature.
[0092] Many milestones in modern biology have been achieved through the study of bacteriophages. Over the past few years, the number of sequenced phage genomes has steadily increased. The National Center for Biotechnology Information (NCBI) phage database has registered over 530 phage gene sequences, more than three times the number in 2005. The biosphere is home to a vast number of phages, and their genomes contain a high proportion of genes with unknown functions. Therefore, studying phage genomes provides a deeper understanding of phages and their interactions with their hosts and the environment.
[0093] In summary, all methods for assembling genome fragments are within the scope of protection of the present invention. The present invention does not limit the scope of the genome.
[0094] In some specific embodiments of the present invention, the genome of the present invention includes but is not limited to a phage genome.
[0095] Bacteriophages (phages) are a class of viruses that attack bacteria (including actinomycetes, fungi, and prokaryotes). They are non-cellular organisms with properties similar to other viruses, primarily composed of proteins and nucleic acids (DNA or RNA). They are widely distributed in nature and can be found in soil, air, water, or within organisms. In 1977, the first complete genome sequencing of the single-stranded DNA phage ψX 174 was completed, consisting of 5,386 base pairs. The first double-stranded DNA phage to be completely sequenced was the lambda phage, which contained 48,502 base pairs. Subsequently, the sequencing of the T7 phage, containing 39,930 base pairs, was completed. Ten years later, the first double-stranded tailed phage was completely sequenced. It belonged to the L5 mycobacteriophage and could infect non-Escherichia coli. Since then, with the development of DNA sequencing technology, a large number of phage genome sequences have been determined, making phages play an increasingly important role in the research process of molecular biology and achieving many milestone research results.
[0096] It is well known to those skilled in the art that phage genome sizes vary, ranging from 3,435 bp for Capsococcus phage L5 to 316,674 bp for Pseudomonas phage 201phi2-1. Furthermore, most phages with larger genomes (greater than 125 kbp) are myotail phages (with contractile tails), with the largest long-tail phage genome being Bacillus phage SPB c2 (134,416 bp).
[0097] Phage populations exhibit remarkable genetic diversity. Generally speaking, phage genomes that share no common host exhibit little sequence similarity, even when their host bacteria are somewhat related. For example, there is no significant nucleotide sequence similarity between four Streptomyces phage genomes and 50 Mycobacterium phage genomes, even though both host bacteria belong to the genus Actinomycetes.
[0098] When different phages infect the same bacterial host, they exchange information during the proliferation process, and common nucleotide sequences may appear. There are many examples of phages with common hosts having related sequences. For example, 30 phage genomes isolated from Pseudomonas (33), Staphylococcus (48), and Mycobacterium tuberculosis (50) have related sequences. However, new studies have found that phages with the same host may have little or no sequence similarity. For example, Escherichia coli K-12 is a common host of λ phage and T4 phage, but the two phages have completely different lifestyles, and the sequence similarity between the two phages is also very small. Another study used the Gepand program to analyze the relationship between the nucleotide sequences of 30 mycobacterial phages and 50 Pseudomonas phages isolated from a common bacterial host, and the comparison revealed several points. First, there is significant nucleotide sequence similarity in each of the two phage genomes, but there is no sequence similarity between the two genomes. Second, even when phages infect the same host, there are huge genetic differences between them.
[0099] Phage genomics research has made tremendous progress in the past few years. Although definitive answers to the questions about phage diversity and evolutionary pathways remain, our understanding of these questions is becoming increasingly clear, and the foundation for relevant research has been laid. In the coming years, with the advancement of sequencing technology, more new phage sequence information will be available. Furthermore, the use of phage agents to control bacterial infections has shown some therapeutic promise. However, the widespread drug resistance of pathogens urgently requires alternative approaches to address this threat. Therefore, phage therapy or combined antibiotic therapy may become a very valuable approach. However, to ensure the safety and controllability of phage therapy, more detailed and definitive experimental evidence is needed for the biological properties of phages and the specific interactions between phages and host bacteria. However, to date, most of the understanding of bacterial susceptibility to phages is based on in vitro studies. Further research is needed to understand how phages interact with bacteria in vivo and how bacteria evade phage lysis. The study of the functional genes of the large number of newly discovered phages and their application in biology and biotechnology will be a key direction for future phage research.
[0100] Therefore, the phage genome fragment assembly method provided by the present invention will provide important technical support for the sequence and function research of phages, especially the research on their therapeutic functions.
[0101] In some specific embodiments of the present invention, the step C further comprises an activation step after the assembly;
[0102] The activation includes but is not limited to: taking the host and inoculating it with Ca 2+ or Mg 2+ Culture in culture medium at 37°C for not less than 6 h.
[0103] In some specific embodiments of the present invention, the evaluation criteria for the success of the assembly method include, but are not limited to: the appearance of expected plaques or the complete clearing phenomenon on the plate indicates that the phage genome is successfully assembled.
[0104] In a seventh aspect, the present invention also provides a method for assembling a genome, including a method for assembling the above-mentioned genome fragments.
[0105] In some embodiments of the present invention, the genome includes but is not limited to a phage genome.
[0106] In an eighth aspect, the present invention also provides a method for synthesizing an artificial phage, including a method for assembling the above-mentioned genome fragments.
[0107] In a ninth aspect, the present invention also provides a method for assembling DNA multimolecules, including the above-mentioned method for assembling genomic fragments.
[0108] In a tenth aspect, the present invention also provides a method for DNA cloning, including the method for assembling the above-mentioned genomic fragments.
[0109] The beneficial effects of the present invention include but are not limited to:
[0110] 1. Successfully assembled multiple (≥5) large phage genome fragments (≥10kb) into a complete genome, overcoming the difficulties of conventional in vitro Gibson Assembly for assembling large fragments;
[0111] 2. The successfully assembled phage genome has the same activity as a natural phage, overcoming the current technical difficulty in activating phage genomes assembled in yeast;
[0112] 3. The genome assembly achieved by this invention is independent of the target vector and can complete the assembly and activation of the phage genome in one step, avoiding the tedious screening steps after in vitro Golden Gate Assembly and in vivo assembly in yeast, greatly reducing the experimental cycle and cost;
[0113] 4. This invention is one of the key steps in synthesizing artificial phages. By combining this invention with synthetic biology techniques such as constructing phage element libraries, site-directed mutagenesis, and de novo synthesis, artificial phages with the potential to be used clinically to treat pathogens can be synthesized.
[0114] 5. The genome assembly that can be achieved by this invention is not limited to phage genomes, but can be extended to the assembly of other genomes.
[0115] In summary, the present invention enables direct assembly of phage genome fragments obtained by PCR or de novo synthesis in E. coli, thereby laying a technical foundation for the synthesis of artificial phages with potential for clinical treatment of pathogens. This method can be used to synthesize artificial phages, improve phage therapy, and treat bacterial infections, particularly those caused by clinically multidrug-resistant bacteria. The present invention has a short experimental cycle, good universality, and high success rate for phage genome assembly, which is conducive to promoting the synthesis of artificial phages and improving phage therapy, and has a promising market prospect. BRIEF DESCRIPTION OF THE DRAWINGS
[0116] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for describing the embodiments or the prior art.
[0117] FIG1 shows a flowchart of the assembly of phage genome fragments provided by the present invention;
[0118] Figure 2 shows examples of assembly results of 4 to 5 10 kb genomic fragments using PH-Kp7215-A and PH-Kp5295 of the present invention (all clear); wherein A shows the combination of in vivo assembly in E. coli with the assistance of Gibson Assembly in vitro; B shows the combination of in vivo assembly in E. coli with the assistance of Gibson Assembly in vitro; C shows the direct assembly of the genome in E. coli in vivo;
[0119] Figure 3 shows an example of a negative control, where the host bacteria Kp7215 was plated (grown with host bacteria);
[0120] Figure 4 shows a comparative example: an example of the assembly results of 5 to 10 kb genomic fragments of PH-Kp5295 by Gibson Assembly in vitro only (grown with host bacteria);
[0121] Figure 5 shows an example of a negative control for the assembly of phage PH-Kp5295 genome fragments, with one fragment randomly selected (grown over the host bacteria);
[0122] Figure 6 shows a comparative example: a gel image of the assembly results of 5 10 kb genomic fragments of PH-Kp5295 by Gibson Assembly in vitro; in the figure, the maker is the 1 kb extent; A- is a genomic fragment that did not undergo Gibson Assembly; A1 is the result of Gibson Assembly of the genomic fragment for 15 minutes, and gDNA1 is the result of Gibson Assembly of gDNA for 15 minutes, i.e., genome circularization, which serves as a control for the assembly effect; A1-5, gDNA1-5 are the genomic fragment and gDNA Gibson Assembly reactions for 15 minutes, 30 minutes, 45 minutes, 60 minutes, and 75 minutes, respectively; it can be seen that there is a significant difference in the size of the fragment assembly results and the complete genome, with the complete genome being around 50 kb, while the Gibson assembly product is around 20-30 kb, and there are DNA fragments that have not been assembled;
[0123] Figure 7 shows a comparative example: a gel image of the in vitro Gibson Assembly results of ten 2kb to 7kb genomic fragments of PH-Kp9495-AB1; the figure is the same as Figure 6, except that the first two markers used, in addition to the 1kb extent, are a 1kb DNA ladder and a DL15000 DNA marker, respectively. The reaction times for the genomic fragment and gDNA Gibson Assembly were 45 min, 60 min, 75 min, 90 min, and 105 min. It can be seen that there is a significant difference between the size of the fragment assembly results and the complete genome, with the complete genome being approximately 50 kb, while the maximum size of the Gibson assembly product does not exceed 15 kb, indicating the presence of a large number of unassembled DNA fragments.
[0124] Figure 8 shows examples of assembly results of 6 ∼15 kb genomic fragments using the Palz-3 of the present invention (completely clear and with plaques); wherein A shows the combination of in vivo assembly in E. coli with the assistance of in vitro Gibson Assembly; B shows the combination of in vivo assembly in E. coli with the assistance of in vitro Gibson Assembly; C shows the direct assembly of the genome in E. coli;
[0125] Figure 9 shows a comparative example: an example of the assembly results of 6 ~15 kb genomic fragments of Palz-3 by Gibson Assembly in vitro only (grown with host bacteria);
[0126] Figure 10 shows an example of a negative control, where the host bacteria Pao1 is plated (grown with host bacteria);
[0127] Figure 11 shows an example of a negative control for the assembly of Palz-3 phage genome fragments, where five randomly selected fragments were assembled in vivo in E. coli (grown to full host bacteria);
[0128] Figure 12 shows examples of assembly results of ten 2 kb to 7 kb PH-Kp9495-AB1 genome fragments using the present invention (complete clear and plaque-grown); wherein A shows direct genome assembly in E. coli; B shows in vivo assembly in E. coli combined with in vitro Gibson Assembly assistance; and C shows in vivo assembly in E. coli combined with in vitro Gibson Assembly assistance.
[0129] FIG13 shows a comparative example: an example of the assembly results of ten 2 kb to 7 kb PH-Kp9495-AB1 genome fragments by in vitro Gibson Assembly only (grown over the host bacteria);
[0130] Figure 14 shows an example of a negative control for the assembly of phage PH-Kp9495-AB1 genome fragments, where six randomly selected fragments were assembled in vivo in E. coli (grown to full host bacteria);
[0131] Figure 15 shows an example of a negative control, where the host bacteria Kp9495 was plated (grown with host bacteria);
[0132] Figure 16 shows an example of the results of cloning a 1 kb fragment using the psgRNA N20 GFP plasmid of the present invention; wherein A shows the combination of in vivo assembly in E. coli and in vitro Gibson Assembly; B shows the direct assembly of the plasmid fragment in E. coli;
[0133] Figure 17 shows an example of a negative control, where a plasmid fragment and a vector are used as negative controls;
[0134] Figure 18 shows an example of the assembly results of 12 2.7-5 kb, 13 2.2-5 kb, 14 2.6-4.7 kb, and 15 2.5-4.5 kb PH-Kp9495-AB1 genome fragments using the present invention (all clear); wherein, A shows the assembly of 12 2.7-5 kb PH-Kp9495-AB1 genome fragments by combining in vivo assembly in Escherichia coli with the assistance of in vitro Gibson Assembly; B shows the assembly of 13 2.2-5 kb PH-Kp9495-AB1 genome fragments by combining in vivo assembly in Escherichia coli with the assistance of in vitro Gibson Assembly; C shows the assembly of 14 2.6-4.7 kb PH-Kp9495-AB1 genome fragments by combining in vivo assembly in Escherichia coli with the assistance of in vitro Gibson Assembly; D shows the assembly of 15 2.5-4.5 kb PH-Kp9495-AB1 genome fragments by combining in vivo assembly in Escherichia coli with the assistance of in vitro Gibson Assembly.
[0135] Figure 19 Comparative example: A, B, C, and D are examples of the assembly results of 12 2.7-5 kb, 13 2.2-5 kb, 14 2.6-4.7 kb, and 15 2.5-4.5 kb PH-Kp9495-AB1 genome fragments by in vitro Gibson Assembly (grown with host bacteria);
[0136] FIG20 shows an example of a negative control, where 15 consecutive intact PH-Kp9495-AB1 genomic fragments of 2.5 to 4.5 kb were activated using stellar / pRARE without a homologous recombination system (grown to full host bacteria). DETAILED DESCRIPTION
[0137] The present invention discloses expression element combinations, expression vectors, hosts, applications and assembly methods of genomic fragments. Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters for implementation. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0138] The present invention adopts the following technical solutions:
[0139] 1. Preparation of phage genome fragments to be assembled: First, split the phage genome into multiple fragments by designing primers. The ends of adjacent, spliced genomic fragments should contain at least 40-100 bp of homology. If the number of assembled fragments is large, the length of the homology arms can be appropriately increased. At the same time, the absolute value of the secondary structure free energy of the homology region and the region 20 bp downstream at 50°C should be ensured to be small (smaller secondary structure free energy theoretically means better assembly, as predicted by NUPACK). Prepare the phage genome fragments to be assembled by PCR and gel recovery.
[0140] 2. In vitro optimal Gibson assembly reaction condition test: The optimal reaction temperature and reaction time were selected by setting three different reaction temperatures of 37°C, 42°C, and 50°C and five different reaction times of 15 min, 30 min, 45 min, 60 min, and 75 min (the reaction time can be adjusted appropriately according to the length and number of assembled fragments);
[0141] 3. In vitro Gibson Assembly: Perform Gibson Assembly using the optimal reaction temperature and time determined in the previous step. Each reaction system contains all genomic fragments, at 60 fmol per fragment. The premix used in the Gibson Assembly reaction is the ER mix provided by the Synthesis and Editing Platform of the National GeneBank.
[0142] 4. In vivo assembly in E. coli and phage activation: The efficiency of in vitro assembly of large DNA fragments is very low. Only a very small fraction of all fragments may be assembled into a complete genome in the final reaction mixture, while the majority remain unassembled fragments or 2-4 spliced intermediates. The efficiency of in vivo assembly of large DNA fragments is much higher than in vitro assembly. A key factor affecting in vivo assembly efficiency is the probability that all fragments enter the same competent cell. Therefore, to further improve assembly efficiency and increase the yield of complete assembled products, combining in vitro and in vivo assembly is being considered. Initial in vitro assembly ensures that a large number of large fragments can be spliced together. Subsequently, in vivo assembly, based on this foundation, greatly increases the probability that all fragments enter the same competent cell for in vivo recombination. Furthermore, given that the assembly of a complete phage genome requires verification by activation in the intermediate host, E. coli, direct assembly in E. coli is currently our preferred approach. This allows us to skip the tedious step of screening for a complete genome and complete assembly and activation in a single step.
[0143] Our laboratory maintains Escherichia coli DH10B strains containing the pRARE plasmid expressing rare codons, a strain commonly used to activate phage genomes. We also have the pKD46 plasmid, which contains the lambda Red homologous recombination system. The Lambda Red homologous recombination system, characterized by short homologous sequences (40-60 bp) and high recombination efficiency, consists of three lambda phage genes: exo, bet, and gam, encoding the Exo, Beta, and Gam proteins, respectively (see the attached diagram for a schematic diagram of the Lambda Red homologous recombination system). The Exo protein is a nuclease, a circular trimer with a central hollow channel that can accommodate double-stranded DNA molecules at one end and single-stranded DNA at the other. Exo proteins bind to the ends of double-stranded DNA and degrade it from the 5' end to the 3' end, forming 3' sticky ends. Beta protein is an annealing protein that plays a crucial role in Red homologous recombination. It tightly binds to the 3' overhang, preventing DNA degradation by single-stranded nucleases and mediating the annealing of complementary single-stranded DNA. The phage genome fragments to be assembled contain 40-100 bp of homology. When Exo protein digestion of the 5' end exposes a 3' overhang, the 3' overhangs of the homologous regions of adjacent genomic fragments anneal under the guidance of Beta protein. Once the double-stranded DNA annealing is complete, Beta protein dissociates from the DNA double strands. Gam protein is a 16 kDa polypeptide that binds to the RecBCD exonuclease, inhibiting its demarcation of foreign DNA and preventing host degradation of foreign DNA after entry into the cell.
[0144] The two plasmids pRARE and pKD46 can coexist in Escherichia coli DH10B. The pKD46 plasmid expressing the homologous recombination system is transformed into the DH10B / pRARE Escherichia coli commonly used for phage genome activation, thus constructing an intermediate host Escherichia coli that can achieve assembly and activation in one step.
[0145] Therefore, based on the above experimental design ideas, the present invention aims to realize the direct assembly of phage genome fragments obtained by PCR or de novo synthesis in E. coli. This goal can be achieved by two technical routes: 1. Direct assembly of phage genome in E. coli; 2. Assembly method combining in vivo assembly in E. coli with in vitro Gibson Assembly, that is, after completing the in vitro Gibson Assembly reaction, the mixture obtained after the reaction is directly transferred into E. coli DH10B competent cells containing the pKD46 plasmid of the lambda Red homologous recombination system for in vivo assembly in E. coli. This E. coli also contains a pRARE plasmid expressing rare codons, which helps to activate the phage genome in the intermediate host E. coli. The competent cells after transformation are cultured in a Ca-containing 2+ The cells were incubated in LB medium for 6 h. After the incubation, the cells were taken out and vortexed with 5% chloroform to break the intermediate host Escherichia coli and release the activated phage particles.
[0146] 5. Verification of the success of assembly: All phage genomes tested for assembly have been previously verified to be able to be successfully activated to obtain active phage particles. Therefore, if the phage genome is fully assembled, it can also be successfully activated to obtain active phage particles, which have the ability to infect its own host. Centrifuge the mixed solution after vortexing in the previous step and carefully aspirate the supernatant. Co-culture with the host bacteria in the logarithmic growth phase at 37°C for 4-5h, and spread on double-layer plates (solid LB plate on the lower layer, soft agar on the upper layer, and Ca added to the upper and lower layers according to the needs of different phage activation). 2+ or Mg 2+ ) Culture at 37℃ for at least 6h. If the expected plaques appear or the plate becomes completely clear, it indicates that the phage genome is assembled successfully.
[0147] The present invention introduces the implementation of this method by assembling the genome of Klebsiella pneumoniae phage as an example, and can also be applied to the assembly of other phage genomes, such as Pseudomonas aeruginosa, Acinetobacter baumannii, etc.
[0148] Currently, attempts have been made to assemble up to 10 phage genome fragments of 2kb to 7kb, and the goal is to achieve the assembly of at least 15 to 10kb phage genome fragments.
[0149] Attempts have been made to assemble phage genomes whose hosts are Gram-negative bacteria. For phages whose hosts are Gram-positive bacteria, cell wall-deficient L-form bacteria, such as L-form Listeria, have been reported as highly effective intermediate hosts for activation. Future phage genome assembly could extend beyond E. coli. After transforming these bacteria, such as by introducing homologous recombination systems, assembly could be attempted in these bacteria, potentially achieving transformation, assembly, and activation in a single step.
[0150] The beneficial effects of the present invention include but are not limited to:
[0151] The present invention can be used to transform and synthesize artificial phages, which can be used for further improved phage therapy.
[0152] Compared with the existing phage genome assembly technology, the present invention achieves the effect of completing assembly and activation in one step.
[0153] ① The success rate is greatly improved compared to in vitro Gibson assembly (attempts to assemble the genome directly using in vitro Gibson assembly were unsuccessful, as both the gel run results and phage genome activation verification indicated assembly failure);
[0154] ② Compared with in vitro Golden Gate Assembly, this assembly technology does not rely on a target vector and can complete phage genome assembly and activation in one step, avoiding tedious screening steps and greatly reducing experimental cycles and costs;
[0155] ③ Compared with in vivo assembly in yeast, this assembly technology only takes 2 days to complete when the genome fragments are prepared, while yeast assembly requires at least 1 week. Yeast assembly also requires PCR verification and positive screening, as well as activation in E. coli after phage release.
[0156] This method has a short experimental cycle, good universality and a high success rate.
[0157] This invention achieves the first direct assembly of large phage genome fragments in E. coli. This technology allows for the transformation, assembly, and activation of phage genomes in a single step, significantly shortening experimental cycles and improving the efficiency of artificial phage engineering. This invention is also applicable to the assembly of large (and small) fragments in other scenarios and can be used in routine molecular cloning experiments.
[0158] The raw materials and reagents used in the genome fragment expression element combination, expression vector, host, application, and assembly method provided by the present invention are all commercially available. The present invention is further described below with reference to the following examples:
[0159] The present invention will be further described below in conjunction with the embodiments:
[0160] Example 1 Klebsiella pneumoniae (Kp) phage PH-Kp9495-AB1, PH-Kp5295, and PH-Kp7215-A genomes were assembled into 4-5 ~10 kb fragments.
[0161] Primers used for fragment preparation:
[0162] Table 1
[0163]
[0164]
[0165] Reaction mixture used for PCR: Hot Start High-Fidelity 2X Master Mix.
[0166] Table 2. PH-Kp7215-A 4 fragments:
[0167]
[0168] Table 3. PH-Kp9495-AB1 5 fragments:
[0169]
[0170] Table 4. PH-Kp5295 5 fragments:
[0171]
[0172] Gibson Assembly premix: ER mix produced by the National Gene Bank Synthesis and Editing Platform
[0173] In vitro Gibson Assembly reaction conditions: reaction temperature 42°C, reaction time 75 min
[0174] In vitro Gibson assembly reaction system: 60 fmol of each genomic fragment + ddH2O to make up 5 μL
[0175] (Total volume of fragments and water: 5 μL) + 15 μL ER mix
[0176] Escherichia coli strains: DH10B / pRARE and DH10B / pRARE / pKD46 strains preserved by the research group
[0177] Each phage assembly experiment group includes three types:
[0178] 1. Only in vitro Gibson Assembly was performed, and the reaction mixture was liquefied and transferred to the E. coli DH10B / pRARE strain for activation, that is, the in vitro Gibson Assembly effect was tested as a comparative example;
[0179] 2. First, perform in vitro Gibson Assembly, and then liquefy the reaction mixture and transfer it into the E. coli DH10B / pRARE / pKD46 strain containing a homologous recombination system, that is, to test the assembly effect of the combination of in vivo E. coli assembly and in vitro Gibson Assembly in the present invention;
[0180] 3. Without performing in vitro Gibson Assembly, all fragments were directly transferred into the E. coli DH10B / pRARE / pKD46 strain containing the Lambda Red homologous recombination system, that is, to test the assembly effect of phage genome fragments directly assembled in E. coli in vivo;
[0181] The amount of fragments used in the three different experimental groups was 60 fmol / fragment.
[0182] Three parallel experiments were set up for each experimental group.
[0183] Control settings:
[0184] 1. Positive control: The extracted phage genomic DNA is activated with the intermediate host DH10B / pRARE and the intermediate host DH10B / pRARE / pKD46. In theory, plaques or clear results should appear in the positive control results.
[0185] 2. Negative control:
[0186] a. Randomly selected genomic fragments (e.g., PH-Kp5295 first fragment; PH-Kp9495-AB1 fourth fragment);
[0187] b. Phage host bacteria Kp9495, Kp7215, Kp5295;
[0188] c. Competent DH10B / pRARE / pKD46 was subjected to the same experimental procedures as the experimental group, but without transforming the fragment or genome to eliminate the interference of chloroform absorption after cell disruption.
[0189] In theory, the negative control results should be filled with natural host bacteria of the phage.
[0190] Experimental operation:
[0191] 1. Preparation of DH10B / pRARE / pKD46 and DH10B / pRARE competent cells:
[0192] A. Isolate Monoclonal Colonies by Streaking: Prepare the strain from the glycerol stock and streak using the "three-line method." For the DH10B / pRARE / pKD46 strain, culture at 30°C on solid LB plates supplemented with ampicillin and chloramphenicol. Monoclonal colonies of appropriate size will grow after approximately two days of incubation. For the DH10B / pRARE strain, culture at 37°C on solid LB plates supplemented with chloramphenicol for approximately one day.
[0193] B. Overnight bacterial preparation: Monoclonal colonies obtained above were picked and transferred to liquid LB medium. For the DH10B / pRARE / pKD46 strain, the LB medium should contain arabinose at a final concentration of 10 mM to induce expression of the Lambda Red homologous recombination system. In addition, the medium should contain ampicillin and chloramphenicol. The medium should be cultured at 30°C. For the DH10B / pRARE strain, the LB medium should contain chloramphenicol and be cultured at 37°C.
[0194] C. Logarithmic Bacterial Preparation: Calculate the required logarithmic volume of competent cells based on the desired 100X volume. Cultivate the DH10B / pRARE strain at 37°C to an OD600 of 0.5-0.55; cultivate the DH10B / pRARE / pKD46 strain at 30°C to an OD600 of 0.5-0.55. Use the same liquid LB medium as in the previous step for both strains.
[0195] D. Competent cell preparation: The two different competent E. coli cells were prepared using the calcium chloride method. Both competent cells were prepared in 200 μL of 100X culture.
[0196] 2. Transformation of E. coli DH10B / pRARE / pKD46, DH10B / pRARE:
[0197] Experimental group 1: 60 fmol / fragment, 15 μL ER Mix, react at 42°C for 90 min. The reaction mixture was liquefied and transferred into E. coli DH10B / pRARE competent cells. The mixture was added to the competent cells, gently mixed, and then incubated on ice for 30 min. Heat shock was performed at 42°C for 90 s, followed by another 3 min on ice. 1 ml of 5 mM Ca was added. 2+ LB medium, 37 ° C, 220 rpm culture.
[0198] Experimental group 2: 60 fmol / fragment, 15 μL ER Mix, react at 42°C for 90 min. The reaction mixture was transferred into E. coli DH10B / pRARE / pKD46 competent cells. The mixture was added to the competent cells, gently mixed, and then incubated on ice for 30 min. Heat shock was performed at 42°C for 90 s, followed by another 3 min on ice. 1 ml of 5 mM Ca was added.2+ LB medium, 37 ° C, 220 rpm culture.
[0199] Experimental group 3: 60 fmol / ml of fragment was directly transferred into E. coli DH10B / pRARE / pKD46 competent cells. The fragment mixture was added to the competent cells, mixed gently, and then placed on ice for 30 min, heat-shocked at 42°C for 90 s, and placed on ice for another 3 min. 1 ml of 5 mM Ca 2+ LB medium, 37 ° C, 220 rpm shaking culture.
[0200] Negative control 1: Randomly select a genomic fragment and take 60 fmol directly into E. coli DH10B / pRARE / pKD46 competent cells. Add the fragment mixture to the competent cells, mix gently, and then place on ice for 30 minutes, heat at 42℃ for 90 seconds, and place on ice for 3 minutes. Add 1 ml of 5 mM Ca 2+ LB medium, 37 ° C, 220 rpm shaking culture.
[0201] Negative control 2: Randomly select a tube of DH10B / pRARE / pKD46 competent cells and do not transform any fragments or genomes. Other operations are consistent with the experimental group. In other words, ice bath for 30 minutes, heat shock at 42℃ for 90 seconds, ice bath for 3 minutes, add 1 ml of 5mM Ca 2+ LB medium, 37℃, 220rpm shaking culture
[0202] Positive control: 60 fmol of the extracted phage genomic DNA was directly transferred into E. coli DH10B / pRARE / pKD46 and DH10B / pRARE competent cells. The genomic DNA was added to the competent cells, gently mixed, and then placed on ice for 30 minutes, heat-shocked at 42°C for 90 seconds, and then placed on ice for 3 minutes. 1 ml of 5 mM Ca 2+ LB medium, 37 ° C, 220 rpm shaking culture.
[0203] 3. One-step assembly and activation of the genome: Samples were taken at three time points: 6h, 8h, and overnight. About 350μL was taken at each time point. After taking the 8h sample, the shaker temperature was adjusted to 22°C. Chloroform with a final concentration of 5% was added to the sample, vortexed for at least 40s, and centrifuged at 14000rpm for 5min. Take the supernatant after centrifugation and use a smaller-scale pipette to aspirate the supernatant in small amounts multiple times. About 200μL of supernatant can be obtained. 200μL of supernatant and 300μL of the natural host bacteria of the corresponding phage in the logarithmic phase were mixed and incubated at 37°C for 4-5h. Afterwards, a double-layer agar plate was spread, and 3ml of 5mM Mg was added to the mixture after incubation. 2+Soft agar, vortex thoroughly and then spread on 5mM Mg 2+ Place the plate on a solid LB plate and incubate at 37°C for at least 4-6 hours after solidification to observe the assembly results. Clearance or plaques indicate successful assembly. A plate covered with the phage's natural host bacteria, i.e., no plaques, indicates a failed assembly. To better demonstrate plaques or clearing, a double layer of agar plates containing 300 μL of the natural host bacteria in logarithmic phase was also plated as a negative control.
[0204] Assembly result:
[0205] Comparative example: The gel image of the Gibson Assembly assembly result (see Figure 4) shows that there is a significant difference in the size of the fragment assembly result and the complete genome. The complete genome is about 50kb, while the Gibson Assembly assembly product is about 20-30Kb. There are DNA fragments that have not been assembled, and the gel image results show that the assembly failed.
[0206] In PH-Kp5295 and PH-Kp7215-A comparative examples, the difference between the external Gibson Assembly assembly result and the direct assembly of genome in Escherichia coli and the auxiliary assembly of Gibson Assembly in vitro in the present invention is not much, and the result of all-clear or plaque appears in 3 parallel experiments. However, in the PH-Kp5295 comparative example, the external Gibson Assembly assembly method failed in 3 parallel experiments, while in the direct assembly of genome in Escherichia coli and the auxiliary assembly of Gibson Assembly in vitro in the present invention, there appeared all-clear flat board in 1 experimental group in 3 parallel experiment groups, which also illustrates that the present invention is more conventional in vitro Gibson Assembly assembly in success rate (all successful assembly of 3 phage genomes using the present invention, and 2 successful assemblies of Gibson Assembly in vitro, 1 failure) and performance are more excellent. The negative control was covered with host bacteria, and the positive control was also all-clear flat board.
[0207] Table 5
[0208]
[0209]
[0210] Example 2 Pseudomonas aeruginosa phage Palz-3 genome, assembly of 6 ~15 kb fragments.
[0211] Primers used for fragment preparation:
[0212] Table 6
[0213]
[0214] Reaction mixture used for PCR: Hot Start High-Fidelity 2X Master Mix
[0215] Palz-3 6 clips:
[0216] Table 7
[0217]
[0218] Gibson Assembly premix: ER mix produced by the National GeneBank Synthesis and Editing Platform.
[0219] In vitro Gibson Assembly reaction conditions: reaction temperature 42°C, reaction time 75 min
[0220] In vitro Gibson assembly reaction system: 60 fmol of each genomic fragment + ddH2O to make up 5 μL
[0221] (Total volume of fragments and water: 5 μL) + 15 μL ER mix
[0222] Escherichia coli strains: DH10B / pRARE and DH10B / pRARE / pKD46 strains preserved by the research group
[0223] Each phage assembly experiment group includes three types:
[0224] 1. Only in vitro Gibson Assembly was performed, and the reaction mixture was liquefied and transferred to the E. coli DH10B / pRARE strain for activation, that is, the in vitro Gibson Assembly effect was tested as a comparative example;
[0225] 2. First, perform in vitro Gibson Assembly, and then liquefy the reaction mixture and transfer it into the E. coli DH10B / pRARE / pKD46 strain containing a homologous recombination system, that is, to test the assembly effect of the combination of in vivo E. coli assembly and in vitro Gibson Assembly in the present invention;
[0226] 3. Without performing in vitro Gibson Assembly, all fragments were directly transferred into the E. coli DH10B / pRARE / pKD46 strain containing the Lambda Red homologous recombination system, that is, to test the assembly effect of phage genome fragments directly assembled in E. coli in vivo;
[0227] The amount of fragments used in the three different experimental groups was 60 fmol / fragment.
[0228] Three parallel experiments were set up for each experimental group.
[0229] Control settings:
[0230] 1. Positive control: The extracted phage genomic DNA is activated with the intermediate host DH10B / pRARE and the intermediate host DH10B / pRARE / pKD46. In theory, plaques or clear results should appear in the positive control results.
[0231] 2. Negative control:
[0232] a. Five randomly selected phage genome fragments;
[0233] b. The host bacteria of the phage Pao1;
[0234] c. Competent DH10B / pRARE / pKD46 was subjected to the same experimental procedures as the experimental group, but no fragments or genome were transformed to eliminate the interference of chloroform absorbed after cell disruption with the experimental results.
[0235] In theory, the negative control results should be filled with natural host bacteria of the phage.
[0236] Experimental operation:
[0237] 1. Preparation of DH10B / pRARE / pKD46 and DH10B / pRARE competent cells:
[0238] A. Isolate Monoclonal Colonies by Streaking: Prepare the strain from the glycerol stock and streak using the "three-line method." For the DH10B / pRARE / pKD46 strain, culture it at 30°C on solid LB plates supplemented with ampicillin and chloramphenicol. Monoclonal colonies of appropriate size will grow in approximately two days. For the DH10B / pRARE strain, culture it at 37°C on solid LB plates supplemented with chloramphenicol. Monoclonal colonies of appropriate size will grow in approximately one day.
[0239] B. Overnight Culture Preparation: Monoclonal colonies obtained above were individually transferred to liquid LB medium. For the DH10B / pRARE / pKD46 strain, the LB medium should contain arabinose at a final concentration of 10 mM to induce expression of the Lambda Red homologous recombination system and the antibiotics ampicillin and chloramphenicol. Culture was performed at 30°C overnight. For the DH10B / pRARE strain, the LB medium should contain chloramphenicol and be cultured at 37°C overnight.
[0240] C. Logarithmic Bacterial Preparation: Calculate the required logarithmic volume of competent cells based on the desired 100X volume. Cultivate the DH10B / pRARE strain at 37°C to an OD600 of 0.5-0.55; cultivate the DH10B / pRARE / pKD46 strain at 30°C to an OD600 of 0.5-0.55. Use the same liquid LB medium as in the previous step for both strains.
[0241] D. Competent cell preparation: The two different competent E. coli cells were prepared using the calcium chloride method. Both competent cells were prepared in 200 μL of 100X culture.
[0242] 2. Transformation of E. coli DH10B / pRARE, DH10B / pRARE / pKD46:
[0243] Experimental Group 1: 60 fmol / fragment, 15 μL ER Mix, reaction at 42°C for 90 min. The reaction mixture was transfected into E. coli DH10B / pRARE competent cells. Add the mixture to the competent cells, mix gently, and incubate on ice for 30 min. Heat shock at 42°C for 90 s, followed by another 3-min incubation on ice. Add 1 mL of LB medium containing 5 mM Ca2+ and incubate at 37°C, 220 rpm.
[0244] Experimental Group 2: 60 fmol / fragment, 15 μL ER Mix, reaction at 42°C for 90 min. The reaction mixture was liquefied and transformed into E. coli DH10B / pRARE / pKD46 competent cells. The mixture was added to the competent cells and gently mixed. The cells were incubated on ice for 30 min, heat-shocked at 42°C for 90 s, and then incubated on ice for another 3 min. The cells were then added with 1 mL of LB medium containing 5 mM Ca2+ and cultured at 37°C at 220 rpm.
[0245] Experimental Group 3: 60 fmol / ml of the fragment was directly transferred into E. coli DH10B / pRARE / pKD46 competent cells. That is, the fragment mixture was added to the competent cells, mixed gently, and then incubated on ice for 30 minutes. Heat shock was performed at 42°C for 90 seconds, followed by another 3-minute ice bath. 1 ml of LB medium containing 5 mM Ca2+ was added and the cells were cultured at 37°C with a shaker at 220 rpm.
[0246] Negative control 1: Randomly select a genomic fragment and transfer 60 fmol of the fragment mixture directly into E. coli DH10B / pRARE / pKD46 competent cells. Add the fragment mixture to the competent cells, mix gently, and incubate on ice for 30 minutes. Heat shock at 42°C for 90 seconds, and then incubate on ice for another 3 minutes. Add 1 ml of LB medium containing 5 mM Ca2+ and culture at 37°C with a shaker at 220 rpm.
[0247] Negative control 2: Randomly select a tube of DH10B / pRARE / pKD46 competent cells and do not transform any fragments or genomes. Other operations are consistent with the experimental group. In other words, ice bath for 30 minutes, heat shock at 42℃ for 90 seconds, ice bath for 3 minutes, add 1 ml of 5mM Ca 2+ LB medium, 37 ° C, 220 rpm shaking culture.
[0248] Positive control: 60 fmol of the extracted phage genomic DNA was directly transferred into E. coli DH10B / pRARE / pKD46 and DH10B / pRARE competent cells. The genomic DNA was added to the competent cells, gently mixed, and then placed on ice for 30 minutes, heat-shocked at 42°C for 90 seconds, and then placed on ice for another 3 minutes. 1 ml of LB medium containing 5 mM Ca2+ was added and cultured in a shaker at 37°C and 220 rpm.
[0249] 3. One-step genome assembly and activation: Samples are collected at two time points, 6 and 8 hours after incubation, with approximately 350 μL collected at each time point. After the 8-hour sample, adjust the shaker temperature to 22°C. Add chloroform to a final concentration of 5% to the sample, vortex for at least 40 seconds, and centrifuge at 14,000 rpm for 5 minutes. Remove the supernatant after centrifugation and aspirate it repeatedly with a small pipette. Approximately 200 μL of supernatant should be obtained. Mix this 200 μL with 300 μL of the natural host bacteria of the corresponding phage at logarithmic phase and incubate at 37°C for 4-5 hours. Then, spread the mixture onto a double layer of agar plates. Add 3 mL of soft agar containing 5 mM Mg2+ to the mixture near the end of the incubation period. Vortex thoroughly to mix, then spread onto a solid LB plate containing 5 mM Mg2+. Once solidified, incubate at 37°C for at least 4-6 hours before observing the assembly results. Observing clear or plaque-forming results indicates successful assembly. Visually, the plate is covered with the phage's natural host bacteria, indicating no plaques. To better demonstrate plaque formation or clear plate formation, a double-layer agar plate containing 300 μL of the natural host bacteria in logarithmic phase was also plated as a negative control.
[0250] Assembly result:
[0251] The present invention's methods for direct in vivo genome assembly in E. coli and combining in vivo assembly with in vitro Gibson Assembly yielded plaques or clear plates in three parallel experiments. In comparison, pure in vitro Gibson Assembly failed in three parallel experiments, demonstrating that the present invention offers superior results to traditional Gibson Assembly, enabling the successful assembly of up to six 15kb phage genome fragments.
[0252] Table 8
[0253]
[0254]
[0255] Example 3 Klebsiella pneumoniae (Kp) phage PH-Kp9495-AB1 genome, assembly of 6, 8, and 10 fragments.
[0256] Primers used for fragment preparation:
[0257] Table 9
[0258]
[0259]
[0260] PCR reaction mixture: NEB Start High-Fidelity 2X Master Mix PH-Kp9495-AB1 6 fragments:
[0261] Table 10
[0262]
[0263] PH-Kp9495-AB1 8 fragments:
[0264] Table 11
[0265]
[0266] PH-Kp9495-AB1 10 fragments:
[0267] Table 12
[0268]
[0269]
[0270] Gibson Assembly premix: ER mix produced by the National Gene Bank Synthesis and Editing Platform
[0271] In vitro Gibson Assembly reaction conditions: reaction temperature 42°C, reaction time 105 min
[0272] In vitro Gibson assembly reaction system: 60 fmol of each genomic fragment + ddH2O to make up 5 μL
[0273] (Total volume of fragments and water: 5 μL) + 15 μL ER mix
[0274] Escherichia coli strains: DH10B / pRARE and DH10B / pRARE / pKD46 strains preserved by the research group
[0275] Each phage assembly experiment group includes three types:
[0276] 1. Only in vitro Gibson Assembly was performed, and the reaction mixture was liquefied and transferred to the E. coli DH10B / pRARE strain for activation, that is, the in vitro Gibson Assembly effect was tested as a comparative example;
[0277] 2. First, perform in vitro Gibson Assembly, and then liquefy the reaction mixture and transfer it into the E. coli DH10B / pRARE / pKD46 strain containing a homologous recombination system, that is, to test the assembly effect of the combination of in vivo E. coli assembly and in vitro Gibson Assembly in the present invention;
[0278] 3. Without performing in vitro Gibson Assembly, all fragments were directly transferred into the E. coli DH10B / pRARE / pKD46 strain containing the Lambda Red homologous recombination system, that is, to test the assembly effect of phage genome fragments directly assembled in E. coli in vivo;
[0279] The amount of fragments used in the three different experimental groups was 60 fmol / fragment.
[0280] Three parallel experiments were set up for each experimental group.
[0281] Control settings:
[0282] 1. Positive control: The extracted phage genomic DNA is activated with the intermediate host DH10B / pRARE and the intermediate host DH10B / pRARE / pKD46. In theory, plaques or clear results should appear in the positive control results.
[0283] 2. Negative control:
[0284] a. Five randomly selected genomic fragments were directly transformed into the intermediate host DH10B / pRARE / pKD46;
[0285] b. Phage host strain Kp9495;
[0286] c. Competent DH10B / pRARE / pKD46 was subjected to the same experimental procedures as the experimental group, but without transforming the fragment or genome to eliminate the interference of chloroform absorption after cell disruption.
[0287] In theory, the negative control results should be filled with natural host bacteria of the phage.
[0288] Experimental operation:
[0289] 1. Preparation of DH10B / pRARE / pKD46 and DH10B / pRARE competent cells:
[0290] A. Isolate Monoclonal Colonies by Streaking: Prepare the strain from the glycerol stock and streak using the "three-line method." For the DH10B / pRARE / pKD46 strain, culture it at 30°C on solid LB plates supplemented with ampicillin and chloramphenicol. Monoclonal colonies of appropriate size will grow in approximately two days. For the DH10B / pRARE strain, culture it at 37°C on solid LB plates supplemented with chloramphenicol. Monoclonal colonies of appropriate size will grow in approximately one day.
[0291] B. Overnight Culture Preparation: Monoclonal colonies obtained above were individually transferred to liquid LB medium. For the DH10B / pRARE / pKD46 strain, the LB medium should contain arabinose at a final concentration of 10 mM to induce expression of the Lambda Red homologous recombination system and the antibiotics ampicillin and chloramphenicol. Culture was performed at 30°C overnight. For the DH10B / pRARE strain, the LB medium should contain chloramphenicol and be cultured at 37°C overnight.
[0292] C. Logarithmic Bacterial Preparation: Calculate the required logarithmic volume of competent cells based on the desired 100X volume. Cultivate the DH10B / pRARE strain at 37°C to an OD600 of 0.5-0.55; cultivate the DH10B / pRARE / pKD46 strain at 30°C to an OD600 of 0.5-0.55. Use the same liquid LB medium as in the previous step for both strains.
[0293] D. Competent cell preparation: The two different competent E. coli cells were prepared using the calcium chloride method. Both competent cells were prepared in 200 μL of 100X culture.
[0294] 2. Transformation of E. coli DH10B / pRARE, DH10B / pRARE / pKD46:
[0295] Experimental group 1: 60 fmol / fragment, 15 μL ER Mix, react at 42°C for 105 min. The reaction mixture was liquefied and transferred into E. coli DH10B / pRARE competent cells. The mixture was added to the competent cells, gently mixed, and then incubated on ice for 30 min. Heat shock was performed at 42°C for 90 s, followed by another 3 min on ice. 1 ml of 5 mM Ca was added. 2+ LB medium, 37 ° C, 220 rpm culture.
[0296] Experimental group 2: 60 fmol / fragment, 15 μL ER Mix, react at 42°C for 105 min. The reaction mixture was transferred into E. coli DH10B / pRARE / pKD46 competent cells. The mixture was added to the competent cells, gently mixed, and then incubated on ice for 30 min. Heat shock was performed at 42°C for 90 s, followed by another 3 min on ice. 1 ml of 5 mM Ca was added. 2+ LB medium, 37 ° C, 220 rpm culture.
[0297] Experimental group 3: 60 fmol / ml of fragment was directly transferred into E. coli DH10B / pRARE / pKD46 competent cells. The fragment mixture was added to the competent cells, mixed gently, and then placed on ice for 30 min, heat-shocked at 42°C for 90 s, and placed on ice for another 3 min. 1 ml of 5 mM Ca 2+ LB medium, 37 ° C, 220 rpm shaking culture.
[0298] Negative control 1: Randomly select a genomic fragment and take 60 fmol directly into E. coli DH10B / pRARE / pKD46 competent cells. Add the fragment mixture to the competent cells, mix gently, and then place on ice for 30 minutes, heat at 42℃ for 90 seconds, and place on ice for 3 minutes. Add 1 ml of 5 mM Ca 2+ LB medium, 37 ° C, 220 rpm shaking culture.
[0299] Negative control 2: Randomly select a tube of DH10B / pRARE / pKD46 competent cells and do not transform any fragments or genomes. Other operations are consistent with the experimental group. In other words, ice bath for 30 minutes, heat shock at 42℃ for 90 seconds, ice bath for 3 minutes, add 1 ml of 5mM Ca 2+ LB medium, 37 ° C, 220 rpm shaking culture.
[0300] Positive control: 60 fmol of the extracted phage genomic DNA was directly transferred into E. coli DH10B / pRARE / pKD46 and DH10B / pRARE competent cells. The genomic DNA was added to the competent cells, gently mixed, and then placed on ice for 30 minutes, heat-shocked at 42°C for 90 seconds, and then placed on ice for 3 minutes. 1 ml of 5 mM Ca 2+ LB medium, 37 ° C, 220 rpm shaking culture.
[0301] 3. One-step assembly and activation of the genome: Samples were taken at three time points: 6h, 8h, and overnight. About 350μL was taken at each time point. After taking the 8h sample, the shaker temperature was adjusted to 22°C. Chloroform with a final concentration of 5% was added to the sample, vortexed for at least 40s, and centrifuged at 14000rpm for 5min. Take the supernatant after centrifugation and use a smaller-scale pipette to aspirate the supernatant in small amounts multiple times. About 200μL of supernatant can be obtained. 200μL of supernatant and 300μL of the natural host bacteria of the corresponding phage in the logarithmic phase were mixed and incubated at 37°C for 4-5h. Afterwards, a double-layer agar plate was spread, and 3ml of 5mM Mg was added to the mixture after incubation. 2+ Soft agar, vortex thoroughly and then spread on 5mM Mg 2+ Place the plate on a solid LB plate and incubate at 37°C for at least 4-6 hours after solidification to observe the assembly results. Clearance or plaques indicate successful assembly. A plate covered with the phage's natural host bacteria, i.e., no plaques, indicates a failed assembly. To better demonstrate plaques or clearing, a double layer of agar plates containing 300 μL of the natural host bacteria in logarithmic phase was also plated as a negative control.
[0302] Assembly result:
[0303] The success rate of in vitro Gibson Assembly for assembling 6 fragments of 6kb to 9kb in size is high (all clear results in 3 parallel experiments), but when the number of fragments is increased to 8 fragments of 3kb to 7kb, or even 10 fragments of 2kb to 7kb in size, the assembly effect is greatly reduced (only 1 plaque appears in 3 parallel experiments, or even 3 parallel experiments all fail). In comparison, the assembly methods of the present invention that directly assemble the genome in E. coli and combine the in vivo assembly of E. coli with the assistance of in vitro Gibson Assembly have a higher success rate, with 6, 8, and 10 fragments all successfully assembled and all clear results or plaques appearing in 3 parallel experiments. It further illustrates that the invention can achieve the successful assembly of up to 10 phage genome fragments, and is superior to the conventional in vitro Gibson Assembly assembly used in the comparative example in terms of success rate and result stability.
[0304] Table 13
[0305]
[0306]
[0307] Example 4 Cloning of a ~1 kb fragment of the psgRNA (N20_GFP_CmR) plasmid in Escherichia coli
[0308] Primers used for fragment preparation:
[0309] Table 14
[0310]
[0311] PCR reaction mixture: NEB Hot Start High-Fidelity 2X Master Mix
[0312] Fragments and vectors:
[0313] Table 15
[0314]
[0315] Gibson Assembly premix: ER mix produced by the National Gene Bank Synthesis and Editing Platform
[0316] In vitro Gibson Assembly reaction conditions: reaction temperature 50°C, reaction time 15 min
[0317] In vitro Gibson assembly reaction system: 30 fmol of each fragment + ddH2O to make up 5 μL
[0318] (Total volume of fragments and water: 5 μL) + 15 μL ER mix
[0319] Escherichia coli strain: DH10B / pRARE / pKD46 strain preserved by the research group
[0320] The plasmid cloning experimental group includes 2 types:
[0321] 1. First, perform the in vitro Gibson Assembly reaction, then liquefy the reaction mixture and transfer it to DH10B / pRARE / pKD46, thus testing the assembly method of the present invention combining in vivo assembly in E. coli with in vitro Gibson Assembly.
[0322] 2. Without performing an in vitro Gibson Assembly reaction, all fragments were directly transferred into the E. coli DH10B / pRARE / pKD46 strain containing the Lambda Red homologous recombination system, i.e., the effect of direct cloning of plasmid fragments in E. coli in vivo was tested;
[0323] The amount of fragments used in the two different experimental groups was 30 fmol / fragment.
[0324] Three parallel experiments were set up for each experimental group.
[0325] Control settings:
[0326] 1. Positive control: The extracted psgRNA N20 GFP plasmid should theoretically show dense E. coli monoclonal colonies in the positive control results.
[0327] 2. Negative control: plasmid vector and fragment are used as negative controls respectively; theoretically, there should be no or few E. coli monoclonal colonies in the negative control results.
[0328] Experimental operation:
[0329] 1. Preparation of DH10B / pRARE / pKD46 competent cells:
[0330] A. Isolate Monoclonal Colonies by Streaking: Prepare the glycerol stock and streak using the "three-line method." For the DH10B / pRARE / pKD46 strain, culture it at 30°C on solid LB plates supplemented with ampicillin and chloramphenicol. Monoclonal colonies of appropriate size should form in approximately two days.
[0331] B. Overnight bacterial culture preparation: Pick each monoclonal colony obtained above and culture it in liquid LB medium. For the DH10B / pRARE / pKD46 strain, the LB medium should contain 10 mM arabinose to induce the expression of the Lambda Red homologous recombination system. In addition, the LB medium should still contain two antibiotics, ampicillin and chloramphenicol. Culture overnight at 30°C.
[0332] C. Preparation of logarithmic bacteria: Calculate the volume of logarithmic bacteria required based on the desired 100X volume of competent cells. Culture at 30°C until the OD600 is between 0.5 and 0.55 using the same liquid LB medium as in the previous step.
[0333] D. Preparation of competent cells: Prepare the above E. coli competent cells using the “calcium chloride method”. The competent cells are 200 μL 100X.
[0334] 2. E. coli DH10B / PRARE / PKD46 transformation:
[0335] Experimental Group 1: 30 fmol / fragment, 15 μL ER Mix, react at 50°C for 15 minutes. The reaction mixture was transfected into E. coli DH10B / pRARE / pKD46 competent cells. The mixture was added to the competent cells and gently mixed. After incubation on ice for 30 minutes, heat shock was performed at 42°C for 90 seconds, followed by another 3-minute incubation on ice. 1 mL of LB medium was added and incubated at 37°C at 220 rpm for 1 hour. The culture was then centrifuged at 14,000 rpm for 3 minutes. The supernatant and 800 mL of culture medium were aspirated and discarded. The remaining culture medium was used to mix the bacterial pellet and spread onto a solid LB plate.
[0336] Experimental Group 2: 30 fmol / ml of fragment was directly transformed into E. coli DH10B / pRARE / pKD46 competent cells. The fragment mixture was added to the competent cells, gently mixed, and then incubated on ice for 30 minutes. Heat shock was performed at 42°C for 90 seconds, followed by another 3-minute incubation on ice. 1 ml of LB medium was added and incubated at 37°C at 220 rpm for 1 hour. The culture was then centrifuged at 14,000 rpm for 3 minutes. The supernatant and 800 ml of culture medium were aspirated and discarded. The remaining culture medium was used to mix the bacterial pellet and spread on a solid LB plate.
[0337] Negative control: 30 fmol of plasmid fragment or vector was directly transferred into E. coli DH10B / pRARE / pKD46 competent cells. That is, the fragment mixture was added to the competent cells, mixed gently, and then incubated on ice for 30 minutes. Heat shock was performed at 42°C for 90 seconds, and then incubated on ice for another 3 minutes. 1 ml of LB medium was added and cultured on a shaker at 37°C and 220 rpm for 1 hour. After that, the culture was centrifuged at 14,000 rpm for 3 minutes. The supernatant to 800 μL of culture medium was aspirated and discarded. The bacterial pellet was mixed with the remaining culture medium and then coated on a solid LB plate.
[0338] Positive control: 30 fmol of the extracted psgRNA N20 GFP plasmid was directly transformed into Escherichia coli DH10B / pRARE / pKD46 and DH10B / pRARE competent cells. That is, the psgRNA N20 GFP plasmid was added to the competent cells, mixed gently, and then ice-bathed for 30 minutes, heat-shocked at 42°C for 90 seconds, and then ice-bathed for 3 minutes. 1 ml of LB medium was added and cultured on a shaker at 37°C and 220 rpm for 1 hour. After that, the culture solution was centrifuged at 14000 rpm for 3 minutes, and the supernatant to 800 μL of culture medium was aspirated and discarded. The bacterial pellet was mixed with the remaining culture medium and then coated on a solid LB plate.
[0339] result:
[0340] The direct assembly of the genome in E. coli and the combination of in vivo assembly in E. coli and in vitro Gibson Assembly-assisted assembly methods of the present invention can both connect vectors and fragments to construct a complete plasmid, indicating that the present invention is also applicable to conventional molecular cloning experiments.
[0341] Table 16
[0342]
[0343] Example 5 Klebsiella pneumoniae (Kp) phage PH-Kp9495-AB1 genome, assembly of 12, 13, 14, and 15 fragments.
[0344] Primers used for fragment preparation:
[0345] Table 17
[0346]
[0347]
[0348]
[0349]
[0350] PCR reaction mixture: NEB Start High-Fidelity 2X Master Mix PH-Kp9495-AB1 12 fragments:
[0351] Table 18
[0352]
[0353]
[0354] PH-Kp9495-AB1 13 fragments:
[0355] Table 19
[0356]
[0357] PH-Kp9495-AB1 14 fragments:
[0358] Table 20
[0359]
[0360]
[0361] PH-Kp9495-AB1 15 fragments:
[0362] Table 21
[0363]
[0364] Gibson Assembly premix: ER mix produced by the National Gene Bank Synthesis and Editing Platform
[0365] In vitro Gibson Assembly reaction conditions: reaction temperature 42°C, reaction time 105 min
[0366] In vitro Gibson assembly reaction system: 30 fmol of each genomic fragment + ddH2O to make up 5 μL
[0367] (Total volume of fragments and water: 5 μL) + 15 μL ER mix
[0368] Escherichia coli strains: stellar / pRARE and stellar / pRARE / pKD46 strains preserved by the research group
[0369] Each phage assembly experiment group includes three types:
[0370] 1. Only in vitro Gibson Assembly was performed, and the reaction mixture was then liquefied and transferred to the E. coli stellar / pRARE strain for activation, i.e., the in vitro Gibson Assembly effect was tested as a comparative example;
[0371] 2. First, perform in vitro Gibson Assembly, and then liquefy the reaction mixture and transfer it into the E. coli stellar / pRARE / pKD46 strain containing a homologous recombination system, thereby testing the assembly effect of the combined in vivo E. coli assembly and in vitro Gibson Assembly in the present invention;
[0372] 3. Without performing in vitro Gibson Assembly, all fragments were directly transferred into the E. coli stellar / pRARE / pKD46 strain containing the Lambda Red homologous recombination system, that is, to test the assembly effect of phage genome fragments directly assembled in E. coli in vivo;
[0373] The amount of fragments used in the three different experimental groups was 30 fmol / fragment.
[0374] Three parallel experiments were set up for each experimental group.
[0375] Control settings:
[0376] 1. Positive control: The extracted phage genomic DNA is activated with the intermediate host stellar / pRARE and the intermediate host stellar / pRARE / pKD46. In theory, plaques or clear results should appear in the positive control results.
[0377] 2. Negative control:
[0378] a. Randomly select n-1 (n is the number of assembled fragments) genomic fragments, 30 fmol each, and directly transform them into E. coli stellar / pRARE / pKD46;
[0379] b. Phage host strain Kp9495;
[0380] c. All genomic fragments, 30 fmol each, were directly transformed into E. coli stellar / pRARE without a homologous recombination system.
[0381] d. The competent cell stellar / pRARE / pKD46 was subjected to the same experimental procedures as the experimental group, but no fragments or genome were transformed to eliminate the interference of chloroform absorption after cell disruption.
[0382] In theory, the negative control results should be filled with natural host bacteria of the phage.
[0383] Experimental operation:
[0384] 1. Preparation of stellar / pRARE / pKD46 and stellar / pRARE competent cells:
[0385] A. Isolate monoclonal colonies by streaking: Take the bacteria stored in glycerol and streak them using the "three-line method." The stellar / pRARE / pKD46 strain should be cultured at 30°C on solid LB plates (preferably solid SOB plates) with ampicillin and chloramphenicol. Monoclonal colonies of appropriate size will grow in about two days. The stellar / pRARE strain should be cultured at 37°C on solid LB plates (preferably solid SOB plates) with chloramphenicol. Monoclonal colonies of appropriate size will grow in about one day.
[0386] B. Overnight Culture Preparation: Fresh (not refrigerated) monoclonal colonies obtained above were individually transferred to liquid SOB medium. For the stellar / pRARE / pKD46 strain, the SOB medium should contain arabinose at a final concentration of 10 mM to induce expression of the Lambda Red homologous recombination system. In addition, the medium should contain the antibiotics ampicillin and chloramphenicol. Culture should be carried out at 30°C overnight. For the stellar / pRARE strain, the medium should contain chloramphenicol and be cultured at 37°C overnight.
[0387] C. Logarithmic Bacterial Preparation: Calculate the required logarithmic volume of competent cells based on the desired 50X volume of cells. Culture the stellar / pRARE strain at 37°C to an OD600 of 0.5-0.55; culture the stellar / pRARE / pKD46 strain at 30°C to an OD600 of 0.5-0.55. Use the same liquid SOB medium as in the previous step for both strains.
[0388] D. Inoue method for preparing stellar super competent state:
[0389] I. Aliquot the obtained logarithmic bacteria with an OD600 between 0.5 and 0.55 into 50 ml pre-chilled sterile polypropylene centrifuge tubes and chill on ice for 10 minutes until the culture cools to 0°C.
[0390] II. Harvest the bacteria by centrifugation at 2500 g for 10 min at 4°C.
[0391] III. Pour off the culture medium and use a 200 μL pipette to remove any droplets remaining on the wall of the centrifuge tube.
[0392] IV. Add 10 ml of ice-cold Inoue Transformation Buffer to each tube and gently resuspend the bacteria on ice.
[0393] V. Harvest the bacteria by centrifugation at 2500 g for 10 min at 4°C;
[0394] VI. Pour off the transformation solution and use a 200 μL pipette to remove any droplets remaining on the wall of the centrifuge tube.
[0395] VII. Gently resuspend the pellet in 1 ml of ice-cold Inoue transformation buffer per tube and combine into one of the 50 ml tubes;
[0396] VIII. Slowly add DMSO to a final concentration of 7% while gently swirling to mix, then store on ice for 10 minutes.
[0397] IX. Aliquot 200 μL into each tube for later use (freshly prepared competent cells, rather than frozen, are more conducive to assembly).
[0398] 2. Transformation of E. coli stellar / pRARE, stellar / pRARE / pKD46:
[0399] Experimental group 1: 30 fmol / fragment, 15 μL ER Mix, react at 42°C for 105 min. The reaction mixture was liquefied and transferred into E. coli stellar / pRARE competent cells. The mixture was added to the competent cells, gently mixed, and then placed on ice for 30 min. Heat shock was performed at 42°C for 90 s, followed by another 3 min on ice. 1 ml of 5 mM Ca was added. 2+ SOB liquid medium, 37 ° C, 220 rpm culture.
[0400] Experimental group 2: 30 fmol / fragment, 15 μL ER Mix, react at 42°C for 105 min. The reaction mixture was liquefied and transferred into E. coli stellar / pRARE / pKD46 competent cells. The mixture was added to the competent cells, gently mixed, and then incubated on ice for 30 min. Heat shock was performed at 42°C for 90 s, followed by another 3 min on ice. 1 ml of 5 mM Ca was added. 2+ SOB liquid medium, 37 ° C, 220 rpm culture.
[0401] Experimental group 3: 30 fmol / ml of fragment was directly transferred into E. coli stellar / pRARE / pKD46 competent cells. The fragment mixture was added to the competent cells, mixed gently, and then placed on ice for 30 min, heat-shocked at 42°C for 90 s, and placed on ice for another 3 min. 1 ml of 5 mM Ca 2+ SOB liquid medium, 37 ℃, 220 rpm shaking culture.
[0402] Negative control 1: randomly selected n-1 (n is the number of assembled fragments) genomic fragments, 30 fmol of each fragment, were directly transformed into E. coli stellar / pRARE / pKD46, that is, the fragment mixture was added to the competent cells, gently mixed, and then incubated on ice for 30 minutes, heat-shocked at 42℃ for 90 seconds, and then incubated on ice for 3 minutes, and 1 ml of 5 mM Ca 2+ SOB liquid medium, 37 ℃, 220 rpm shaking culture.
[0403] Negative control 2: All genomic fragments, 30 fmol each, were directly transformed into E. coli stellar / pRARE without a homologous recombination system. The fragment mixture was added to the competent cells, gently mixed, and then incubated on ice for 30 minutes, heat-shocked at 42°C for 90 seconds, and then incubated on ice for 3 minutes. 1 ml of 5 mM Ca 2+ SOB liquid medium, 37 ℃, 220 rpm shaking culture.
[0404] Negative control 3: Randomly select a tube of stellar / pRARE / pKD46 competent cells and do not transform any fragments or genomes. Other operations are the same as those of the experimental group. In other words, ice bath for 30 minutes, heat shock at 42℃ for 90 seconds, ice bath for 3 minutes, add 1 ml of 5mM Ca 2+ SOB medium, 37℃, 220rpm shaking culture
[0405] Positive control: 30 fmol of the extracted phage genomic DNA was directly transferred into E. coli stellar / pRARE / pKD46 and stellar / pRARE competent cells. The genomic DNA was added to the competent cells, gently mixed, and then placed on ice for 30 minutes, heat-shocked at 42°C for 90 seconds, and then placed on ice for 3 minutes. 1 ml of the solution containing 5 mM Ca 2+ SOB liquid medium, 37 ℃, 220 rpm shaking culture.
[0406] 3. One-step genome assembly and activation: Samples of approximately 350 μL were collected at three time points: 6 hours, 8 hours, and overnight. After the 8-hour sample, the shaker temperature was adjusted to 22°C. Chloroform was added to the sample at a final concentration of 5%, vortexed for at least 40 seconds, and centrifuged at 14,000 rpm for 5 minutes. The supernatant was collected and aspirated repeatedly using a small pipette. Approximately 200 μL of supernatant was obtained. This 200 μL supernatant was mixed with 300 μL of the natural host bacteria of the corresponding phage at logarithmic phase and incubated at 37°C for 4-5 hours. Next, a double layer of agar plates was plated. Near the end of the incubation, 3 ml of soft agar was added to the mixture, vortexed thoroughly, and plated onto a solid SOB plate. Once solidified, the mixture was incubated at 37°C for at least 4-6 hours before observing the assembly results. Observing clear or plaque-forming results indicates successful assembly. Visually, the plate is covered with the phage's natural host bacteria, indicating no plaques. To better demonstrate plaque formation or clear plate formation, a double-layer agar plate containing 300 μL of the natural host bacteria in logarithmic phase was also plated as a negative control.
[0407] Assembly result:
[0408] In vitro Gibson Assembly failed in three parallel experiments when assembling 12 fragments of 2.7-5 kb, 13 fragments of 2.3-5 kb, 14 fragments of 2.6-4.7 kb, and 15 fragments of 2.5-4.5. In comparison, the assembly method of the present invention combining in vivo assembly of E. coli with the assistance of in vitro Gibson Assembly had a higher success rate. The assembly of 12, 13, 14, and 15 fragments was successful, and the three parallel experiments of assembling 12 and 13 fragments all produced clear or plaque plates. The results of the method were very stable, further demonstrating that the present invention can achieve the successful assembly of up to 15 phage genome fragments, and is superior to the conventional in vitro Gibson Assembly assembly used in the comparative example in terms of success rate and result stability.
[0409] Table 22
[0410]
[0411]
[0412] The above describes in detail the expression element combination, expression vector, host, application and assembly method of the genomic fragment provided by the present invention. This article uses specific examples to illustrate the principles and implementation methods of the present invention. The description of the above embodiments is only used to help understand the method of the present invention and its core concept. It should be pointed out that for those skilled in the art, without departing from the principles of the present invention, the present invention can also be improved and modified in a number of ways, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. An expression element combination, characterized in that Including but not limited to: (I), expression elements in the pRARE plasmid; and (II) Expression elements of the lambda Red homologous recombination system.
2. The expression element combination according to claim 1, wherein The expression elements of the lambda Red homologous recombination system include, but are not limited to, exo, bet, and gam.
3. An expression vector, characterized in that Comprising the expression element combination according to claim 1 or 2.
4. The expression vector according to claim 3, wherein These include, but are not limited to, pRARE plasmid and pKD46 plasmid.
5. A host transformed or transfected with the expression vector according to claim 3 or 4.
6. The host according to claim 5, wherein The host is a prokaryotic organism or a eukaryotic organism, including but not limited to one or more of bacteria, actinomycetes, rickettsia, chlamydia, mycoplasma, cyanobacteria, archaea, yeast and mold.
7. The host according to claim 6, wherein The bacteria include but are not limited to Gram-negative bacteria or Gram-positive bacteria; Preferably, the Gram-negative bacteria include but are not limited to Escherichia coli; more preferably, the Escherichia coli include but are not limited to Escherichia coli DH10B; Preferably, the Gram-positive bacteria include but are not limited to cell wall-deficient L-form bacteria; more preferably, the cell wall-deficient L-form bacteria include but are not limited to L-form Listeria.
8. Use of the expression element combination according to claim 1 or 2, the expression vector according to claim 3 or 4, or the host according to any one of claims 5 to 7 in genomic fragment assembly.
9. Use of the expression element combination according to claim 1 or 2, the expression vector according to claim 3 or 4, or the host according to any one of claims 5 to 7 in one or more of molecular cloning, synthesis of artificial phages, phage therapy, preparation of phage therapy products, detection of microorganisms, preparation of products for detection of microorganisms, prevention and / or treatment of infections or diseases caused by microorganisms, or preparation of drugs for prevention and / or treatment of infections or diseases caused by microorganisms.
10. The use according to claim 9, characterized in that The fragments include but are not limited to: (I), fragments <2 kb; and / or (II), fragments ≥2 kb and <7 kb; and / or (III), fragments ≥7 kb and <10 kb; and / or (IV), fragments ≥7 kb and <10 kb; and / or (V), fragments ≥10 kb.
11. The use according to claim 9 or 10, characterized in that The number of the fragments includes but is not limited to: (I), <5; and / or (II), ≥5 and <10; and / or (III), ≥10 and <15; and / or (IV), ≥15.
12. A method for assembling genome fragments, characterized in that Based on the expression element combination according to claim 1 or 2, the expression vector according to claim 3 or 4, or the host according to any one of claims 5 to 7, the genomic fragments are assembled.
13. The assembly method according to claim 12, wherein: The assembly includes but is not limited to: (I), direct assembly in the host; and / or (II), in vitro Gibson Assembly and in vivo assembly in the host.
14. The assembly method according to claim 12 or 13, characterized in that: Including but not limited to the following steps: Step A: Obtain the genome fragments to be assembled; Step B: perform in vitro Gibson Assembly; Step C: assembly in the host body; The assembly method may include step B or may not include step B.
15. The assembly method according to claim 13 or 14, characterized in that: The fragments include but are not limited to: (I) There is a homologous region of at least 40 to 100 bp at the end; and / or (II) When the number of the fragments is large, the length of the homology arms is increased while ensuring that the secondary structure free energy of the homology region and the region 20 bp downstream at 50°C is small.
16. The assembly method according to any one of claims 13 to 15, characterized in that: The reaction temperature of the in vitro Gibson Assembly is not limited to 37°C to 50°C; Preferably, the reaction temperature of the in vitro Gibson Assembly includes but is not limited to: (I), 42°C or 50°C; and / or (II), 37°C to 42°C; and / or (III), 42℃~50℃; The reaction time of the in vitro Gibson Assembly in step B includes but is not limited to 15 min to 105 min; Preferably, the reaction time of the in vitro Gibson Assembly includes but is not limited to: (I), 15 min, 75 min or 105 min; and / or (II), 15 minutes to 75 minutes; and / or (III), 75min~105min.
17. The assembly method according to any one of claims 13 to 16, characterized in that: In the in vitro Gibson Assembly system, the amount of the fragment is no less than 30 fmol; Preferably, the amount of the fragment includes but is not limited to: (I), 30 fmol to 60 fmol; and / or (II), >60fmol.
18. The assembly method according to any one of claims 14 to 17, characterized in that: The genome includes but is not limited to a phage genome.
19. The assembly method according to claim 18, wherein: After the assembly described in step C, an activation step is also included; The activation includes but is not limited to: taking the host and inoculating it with Ca 2+ or Mg 2+ Culture in culture medium at 37°C for not less than 6 h.
20. The assembly method according to claim 18 or 19, characterized in that: The evaluation criteria for the success of the assembly method include, but are not limited to: if the expected plaques appear or the plate is completely cleared, the phage genome is successfully assembled.
21. A method for assembling a genome, characterized in that The method comprises the assembly method according to any one of claims 12 to 20.
22. The assembly method according to claim 21, wherein: The genome includes but is not limited to a phage genome.
23. A method for synthesizing an artificial bacteriophage, characterized in that: The method comprises the assembly method according to any one of claims 12 to 20.
24. A DNA multi-molecule assembly method, characterized in that: The method comprises the assembly method according to any one of claims 12 to 20.
25. A DNA cloning method, characterized in that The method comprises the assembly method according to any one of claims 12 to 20.
